Targeted Proteomics for the Non-invasive Identification of Fibrosis: Progressing the Diagnosis of Chronic Liver Disease

Underhill Mokdad^*
*Correspondence: Underhill Mokdad, Department of Gastroenterology and Hepatology, Turkey, Email:

Introduction

Chronic Liver Disease (CLD) encompasses a wide spectrum of liver conditions that are primarily characterized by long-standing damage and inflammation of the liver tissue, ultimately leading to the development of fibrosis, cirrhosis and sometimes liver cancer. Fibrosis, the excessive accumulation of extracellular matrix proteins due to liver injury, is a hallmark of CLD and often represents the transition from early liver damage to more severe forms of liver pathology. The progressive nature of fibrosis is strongly associated with worsening liver function, increased risk of complications such as portal hypertension and a poorer prognosis. Therefore, the early detection and accurate assessment of liver fibrosis is crucial for timely intervention and the management of chronic liver diseases. Traditional diagnostic approaches to fibrosis, such as liver biopsy, are invasive, expensive and carry significant risks, highlighting the need for non-invasive, accurate and cost-effective diagnostic tools [1,2].

Description

Targeted proteomics, a field that focuses on the identification and quantification of specific proteins in biological samples, has emerged as a promising approach for the non-invasive diagnosis of liver fibrosis and chronic liver disease. Proteomic profiling allows for a deeper understanding of the molecular mechanisms underlying fibrosis and it offers the potential to identify biomarkers that can facilitate the diagnosis and monitoring of disease progression. In recent years, targeted proteomics has gained attention as a tool for identifying fibrosis-related proteins that can be detected in noninvasive samples such as blood, urine, or saliva. This approach allows clinicians to assess fibrosis status without the need for invasive procedures like liver biopsy, thus reducing patient risk and improving clinical efficiency. This essay explores the progress made in using targeted proteomics for the non-invasive identification of fibrosis, with a focus on the advancements in technology, biomarker discovery and clinical applications.

Conclusion

Targeted proteomics has emerged as a promising tool for the noninvasive diagnosis of liver fibrosis and chronic liver disease. The ability to identify and quantify fibrosis-related biomarkers in biological samples, such as blood, urine, or saliva, offers significant advantages over traditional diagnostic methods, such as liver biopsy. Advances in proteomic technologies, including liquid chromatography-tandem mass spectrometry and multiple reaction monitoring, have significantly improved the sensitivity and accuracy of fibrosis detection. However, challenges remain in the identification and validation of reliable biomarkers, the standardization of proteomic assays and the clinical validation of proteomic tests. With continued research and technological advancements, targeted proteomics has the potential to play a crucial role in the early detection, staging and monitoring of liver fibrosis, ultimately improving the management and treatment of chronic liver diseases.

References

1. Devarbhavi, Harshad, Sumeet K. Asrani, Juan Pablo Arab and Yvonne Ayerki Nartey, et al. "Global burden of liver disease: 2023 update." J Hepatol 79 (2023): 516-537.

Google Scholar, Crossref, Indexed at

2. Niu, Lili, Philipp E. Geyer, Nicolai J. Wewer Albrechtsen and Lise L. Gluud, et al. "Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease." Mol Syst Biol 15 (2019): e8793.

Google Scholar, Crossref, Indexed at